NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALVAIZ (eltrombopag) by Teva is tpo-receptor agonist that interacts with the transmembrane domain of the human tpo-receptor (also known as cmpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production. Approved for immune thrombocytopenia, aplastic anemia, chronic hepatitis c and 4 more indications. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALVAIZ (eltrombopag) is an oral TPO-receptor agonist approved by FDA on November 29, 2023, that stimulates megakaryocyte proliferation and differentiation to increase platelet production. It is indicated for immune thrombocytopenia, aplastic anemia, chronic hepatitis C, non-alcoholic steatohepatitis, HIV infection, chronic hepatitis B, and chronic liver disease. The drug works by binding to the transmembrane domain of the human TPO-receptor (cMpl) and triggering signaling cascades that drive platelet synthesis.
Growth12.5 years to LOE
Early-stage growth product with 12+ years of patent protection offers opportunity to build market presence and expand indications across hematology and hepatology franchises.
Mechanism of Action
TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Indications (7)
Worked on ALVAIZ at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.